The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment.
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system. Depression, or major depressive disorder, is highly prevalent in people with MS and often has a serious impact on quality of life. MDD can be difficult to treat with medications in MS. Transcranial magnetic stimulation (TMS) is a safe and approved treatment for treatment-resistant depression in the general population. However, little is known about the use of TMS for MDD in people with MS. This pilot study will evaluate the safety, feasibility, and preliminary efficacy of TMS for MDD in MS. Participants will receive outpatient neuronavigated-TMS for MDD. Various measures of MS and MDD symptoms will be monitored over the course of treatment. Clinical brain imaging will also be compared before and after TMS.
Study Type
OBSERVATIONAL
Enrollment
12
University of Utah Health
Salt Lake City, Utah, United States
RECRUITINGFeasibility of TMS treatment for MDD, per participant retention rates.
Time frame: 10 weeks
Safety and tolerability, to be evaluated by side effects and adverse events over the course of treatment.
Time frame: 10 weeks
Depression response rates (50% reduction in symptoms) will be measured using MADRS scores before and after treatment.
Time frame: 10 weeks
Depression remission rates will be measured using MADRS scores before and after treatment.
Time frame: 10 weeks
MS lesion burden on MRI will be compared before and after treatment to determine impact of TMS on white matter disease burden.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.